Cited by 1,008T-cell and B-cell ImmunologyCancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

The DOI matches its Crossref record; 41 of the 44 references it cites were found in a registry or an index.

Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25+ regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses

Open access

Sutmuller, Roger P.M., van Duivenvoorde, Leonie M., van Elsas, Andrea, Schumacher, Ton N.M., Wildenberg, Manon E., Allison, James P., Toes, Rene E.M., Offringa, Rienk, Melief, Cornelis J.M.·2001·The Journal of Experimental Medicine

DOI 10.1084/jem.194.6.823PMC PMC2195955

Open this paper in CoChat — free account

Abstract

Therapeutic efficacy of a tumor cell–based vaccine against experimental B16 melanoma requires the disruption of either of two immunoregulatory mechanisms that control autoreactive T cell responses: the cytotoxic T lymphocyte–associated antigen (CTLA)-4 pathway or the CD25+ regulatory T (Treg) cells. Combination of CTLA-4 blockade and depletion of CD25+ Treg cells results in maximal tumor rejection. Efficacy of the antitumor therapy correlates with the extent of autoimmune skin depigmentation as well as with the frequency of tyrosinase-related protein 2180–188–specific CTLs detected in the periphery. Furthermore, tumor rejection is dependent on the CD8+ T cell subset. Our data demonstrate that the CTL response against melanoma antigens is an important component of the therapeutic antitumor response and that the reactivity of these CTLs can be augmented through interference with immunoregulatory mechanisms. The synergism in the effects of CTLA-4 blockade and depletion of CD25+ Treg cells indicates that CD25+ Treg cells and CTLA-4 signaling represent two alternative pathways for suppression of autoreactive T cell immunity. Simultaneous intervention with both regulatory mechanisms is therefore a promising concept for the induction of therapeutic antitumor immunity.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1084/jem.194.6.823

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Signaling by intrathymic cytokines, not T cell antigen receptors, specifies CD8 lineage choice and promotes the differentiation of cytotoxic-lineage T cells
Park, J., Adoro, S., Guinter, T. I., Erman, B., Alag, A., Catálfamo, M., Kimura, M. Y., Cui, Y., Lucas, P. J., Gress, R. E., et al. (2010) · Nature Immunology · doi:10.1038/ni.1840 · Cited by 5,835
Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases
Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M., & Toda, M. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.155.3.1151 · Cited by 5,608
Phenotypic Analysis of Antigen-Specific T Lymphocytes
Altman, J. D., Moss, P. A. H., Goulder, P. J. R., Barouch, D. H., McHeyzer-Williams, M. G., Bell, J. I., McMichael, A. J., & Davis, M. M. (1996) · Science · doi:10.1126/science.274.5284.94 · Cited by 3,544 · cited 1×
“H-2K b tetramers were produced as described previously (20, 21) and stored frozen in Tris-buffered saline/16% glycerol/0.”
Method
CD4+CD25+ Immunoregulatory T Cells Suppress Polyclonal T Cell Activation In Vitro by Inhibiting Interleukin 2 Production
Thornton, A. M., & Shevach, E. M. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.2.287 · Cited by 2,637
CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.
Krummel, M. F., & Allison, J. P. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.2.459 · Cited by 2,245 · cited 2×
“Anderson Cancer Center, Houston, TX), GM-CSF‐producing B16 cell lines BL6/GM-E, BL6/GM18 (18), B16/B7.1 (18), 9H10 ( 19 ), and PC61 (American Type Culture Collection) were cultured in Iscove’s IMDM (BioWhittaker) supplemented with 1 U/ml penicillin, 1 � g/ml streptomycin, 2 � M L -glutamine, 20 � M � -mercaptoethanol…”
MethodSelf-citation
Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4
Takahashi, T., Tagami, T., Yamazaki, S., Uede, T., Shimizu, J., Sakaguchi, N., Mak, T. W., & Sakaguchi, S. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.303 · Cited by 2,233
CTLA-4 can function as a negative regulator of T cell activation
Walunas, T. L., Lenschow, D. J., Bakker, C. Y., Linsley, P. S., Freeman, G. J., Green, J. M., Thompson, C. B., & Bluestone, J. A. (1994) · Immunity · doi:10.1016/1074-7613(94)90071-x · Cited by 2,222
Cytotoxic T Lymphocyte–Associated Antigen 4 Plays an Essential Role in the Function of Cd25+Cd4+ Regulatory Cells That Control Intestinal Inflammation
Read, S., Malmström, V., & Powrie, F. M. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.295 · Cited by 2,206
B7/CD28 Costimulation Is Essential for the Homeostasis of the CD4+CD25+ Immunoregulatory T Cells that Control Autoimmune Diabetes
Salomon, B. L., Lenschow, D. J., Rhee, L., Ashourian, N., Singh, B., Sharpe, A. H., & Bluestone, J. A. (2000) · Immunity · doi:10.1016/s1074-7613(00)80195-8 · Cited by 2,058
Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state.
Takahashi, T., Kuniyasu, Y., Toda, M., Sakaguchi, N., Itoh, M., Iwata, M., Shimizu, J., & Sakaguchi, S. (1998) · International Immunology · doi:10.1093/intimm/10.12.1969 · Cited by 1,566

Flagged first, then by citations

Show all 44 references

3 of the 44 references couldn’t be matched to a known paper.

Sorted by citations

Items 101–200 of 1,000

CTLA-4 blockade in tumor models: an overview of preclinical and translational research.
Grosso, J. F., & Jure‐Kunkel, M. (2013) · Europe PMC (PubMed Central) · Cited by 335
Chapter 8 The Role of NKT Cells in Tumor Immunity
Terabe, M., & Berzofsky, J. A. (2008) · Advances in cancer research · doi:10.1016/s0065-230x(08)00408-9 · Cited by 346
Strategies for designing and optimizing new generation vaccines
Berzofsky, J. A., Ahlers, J. D., & Belyakov, I. M. (2001) · Nature reviews. Immunology · doi:10.1038/35105075 · Cited by 333
Anti–Cytotoxic T-Lymphocyte Antigen-4 Antibody: The First in an Emerging Class of Immunomodulatory Antibodies for Cancer Treatment
Fong, L. H., & Small, E. J. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.8954 · Cited by 320
T cell homeostatic proliferation elicits effective antitumor autoimmunity
Dummer, W., Niethammer, A. G., Baccalà, R., Lawson, B. R., Wagner, N., Reisfeld, R. A., & Theofilopoulos, A. N. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15175 · Cited by 316
The CD28 family: a T-cell rheostat for therapeutic control of T-cell activation
Riley, J. L., & June, C. H. (2004) · Blood · doi:10.1182/blood-2004-04-1596 · Cited by 325
Targeting cytotoxic T‐lymphocyte antigen‐4 (CTLA‐4)
O'Day, S. J., Hamid, O., & Urba, W. J. (2007) · Cancer · doi:10.1002/cncr.23086 · Cited by 309
Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients
Banerjee, D. K., Dhodapkar, M. V., Matayeva, E., Steinman, R. M., & Dhodapkar, K. M. (2006) · Blood · doi:10.1182/blood-2006-03-011353 · Cited by 314
Elucidating the Autoimmune and Antitumor Effector Mechanisms of a Treatment Based on Cytotoxic T Lymphocyte Antigen-4 Blockade in Combination with a B16 Melanoma Vaccine
van Elsas, A., Sutmuller, R. P. M., Hurwitz, A. A., Ziskin, J. L., Villaseñor, J., Medema, J. P., Overwijk, W. W., Restifo, N. P., Melief, C. J. M., Offringa, R., et al. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.4.481 · Cited by 308
Self-citation
Delivering safer immunotherapies for cancer
Milling, L. E., Zhang, Y., & Irvine, D. J. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.05.011 · Cited by 311
Immunomodulatory effects of cyclophosphamide and implementations for vaccine design
Sistigu, A., Viaud, S., Chaput, N., Bracci, L., Proietti, E., & Zitvogel, L. (2011) · Seminars in Immunopathology · doi:10.1007/s00281-011-0245-0 · Cited by 318
Immune Checkpoint Proteins: A New Therapeutic Paradigm for Cancer—Preclinical Background: CTLA-4 and PD-1 Blockade
Weber, J. S. (2010) · Seminars in Oncology · doi:10.1053/j.seminoncol.2010.09.005 · Cited by 309
Cancer and the Immune System: Basic Concepts and Targets for Intervention
Pardoll, D. M. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.05.003 · Cited by 312
Tumor-infiltrating T lymphocytes: Friends or foes?
Yu, P., & Fu, Y.-X. (2006) · Laboratory Investigation · doi:10.1038/labinvest.3700389 · Cited by 299
Efficient loading of dendritic cells following cryo and radiofrequency ablation in combination with immune modulation induces anti-tumour immunity
den Brok, M. H. M. G. M., Sutmuller, R. P. M., Nierkens, S., Bennink, E. J., Frielink, C., Toonen, L. W. J., Boerman, O. C., Figdor, C. G., Ruers, T. J. M., & Adema, G. J. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603341 · Cited by 302
Self-citation
CD4(+)CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers
Kono, K., Kawaida, H., Takahashi, A., Sugai, H., Mimura, K., Miyagawa, N., Omata, H., & Fujii, H. (2005) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-005-0092-8 · Cited by 291
Clinical Use of Anti‐CD25 Antibody Daclizumab to Enhance Immune Responses to Tumor Antigen Vaccination by Targeting Regulatory T cells
Rech, A. J., & Vonderheide, R. H. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.04939.x · Cited by 294
Costimulatory and coinhibitory receptors in anti‐tumor immunity
Driessens, G., Kline, J. P., & Gajewski, T. F. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00771.x · Cited by 303
Control of Autoimmunity by Naturally Arising Regulatory CD4+ T Cells
Hori, S., Takahashi, T., & Sakaguchi, S. (2003) · Advances in immunology · doi:10.1016/s0065-2776(03)81008-8 · Cited by 279
CD86 and CD80 Differentially Modulate the Suppressive Function of Human Regulatory T Cells
Zheng, Y., Manzotti, C. N., Liu, M., Burke, F., Mead, K. I., & Sansom, D. M. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.5.2778 · Cited by 277
Pre-B-cell colony-enhancing factor, whose expression is up-regulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis
Rongvaux, A., Shea, R. J., Mulks, M. H., Gigot, D., Urbain, J., Léo, O., & Andris, F. (2002) · European Journal of Immunology · doi:10.1002/1521-4141(200211)32:11 · Cited by 551
Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines
Zhou, G., Drake, C. G., & Levitsky, H. I. (2005) · Blood · doi:10.1182/blood-2005-07-2737 · Cited by 274
Effective induction of naive and recall T-cell responses by targeting antigen to human dendritic cells via a humanized anti–DC-SIGN antibody
Tacken, P. J., de Vries, I. J. M., Gijzen, K., Joosten, B., Wu, D., Rother, R. P., Faas, S. J., Punt, C. J. A., Torensma, R., Adema, G. J., et al. (2005) · Blood · doi:10.1182/blood-2005-01-0318 · Cited by 276
Characteristics of CD4+CD25+ regulatory T cells in the peripheral circulation of patients with head and neck cancer
Schaefer, C. P., Kim, G. G., Albers, A. E., Hoermann, K., Myers, E., & Whiteside, T. L. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602407 · Cited by 270
The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression
Ghiringhelli, F., Menard, C., Martin, F., & Zitvogel, L. (2006) · Immunological Reviews · doi:10.1111/j.1600-065x.2006.00445.x · Cited by 278
Higher Frequencies of GARP+CTLA-4+Foxp3+ T Regulatory Cells and Myeloid-Derived Suppressor Cells in Hepatocellular Carcinoma Patients Are Associated with Impaired T-Cell Functionality
Kalathil, S. G., Lugade, A. A., Miller, A., Iyer, R. V., & Thanavala, Y. M. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3381 · Cited by 276
Selective Depletion of Foxp3+ Regulatory T Cells Improves Effective Therapeutic Vaccination against Established Melanoma
Klages, K., Mayer, C. T., Lahl, K., Loddenkemper, C., Teng, M. W. L., Ngiow, S. F., Smyth, M. J., Hamann, A., Huehn, J., & Sparwasser, T. D. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1736 · Cited by 267
T cell homeostatic proliferation elicits effective antitumor autoimmunity
Dummer, W., Niethammer, A. G., Baccalà, R., Lawson, B. R., Wagner, N., Reisfeld, R. A., & Theofilopoulos, A. N. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215175 · Cited by 267
The promise of cancer vaccines
Gilboa, E. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1359 · Cited by 268
A reversed CD4/CD8 ratio of tumor-infiltrating lymphocytes and a high percentage of CD4+FOXP3+ regulatory T cells are significantly associated with clinical outcome in squamous cell carcinoma of the cervix
Shah, W., Yan, X., Li, J., Zhou, Y., Chen, H., & Wang, Y. (2010) · Cellular and Molecular Immunology · doi:10.1038/cmi.2010.56 · Cited by 266
Intrapatient Dose Escalation of Anti–CTLA-4 Antibody in Patients With Metastatic Melanoma
Maker, A. V., Yang, J. C., Sherry, R. M., Topalian, S. L., Kammula, U. S., Royal, R. E., Hughes, M. S., Yellin, M. J., Haworth, L. R., Levy, C. L., et al. (2006) · Journal of Immunotherapy · doi:10.1097/01.cji.0000208259.73167.58 · Cited by 264
Oncolytic Immunovirotherapy for Melanoma Using Vesicular Stomatitis Virus
Díaz, R. M., Galivo, F., Kottke, T. J., Wongthida, P., Qiao, J., Thompson, J., Valdes, M., Barber, G. N., & Vile, R. G. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3974 · Cited by 263
Immunoregulatory T cells in tumor immunity
Terabe, M., & Berzofsky, J. A. (2004) · Current Opinion in Immunology · doi:10.1016/j.coi.2004.01.010 · Cited by 259
Tumor-Induced Expansion of Regulatory T Cells by Conversion of CD4+CD25− Lymphocytes Is Thymus and Proliferation Independent
Valzasina, B., Piconese, S., Guiducci, C., & Colombo, M. P. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4217 · Cited by 266
CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion
Kavanagh, B., O'Brien, S., Lee, D., Hou, Y., Weinberg, V., Rini, B., Allison, J. P., Small, E. J., & Fong, L. (2008) · Blood · doi:10.1182/blood-2007-11-125435 · Cited by 256
Self-citation
Dendritic cells expand antigen‐specific Foxp3+CD25+CD4+ regulatory T cells including suppressors of alloreactivity
Yamazaki, S., Inaba, K., Tarbell, K. V., & Steinman, R. M. (2006) · Immunological Reviews · doi:10.1111/j.0105-2896.2006.00422.x · Cited by 257
Selective CD4+ Lymphopenia in Melanoma Patients Treated With Temozolomide: A Toxicity With Therapeutic Implications
Su, Y. B., Sohn, S., Krown, S. E., Livingston, P. O., Wolchok, J. D., Quinn, C. J., Williams, L. J., Foster, T., Sepkowitz, K. A., & Chapman, P. B. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.060 · Cited by 256
Progress on new vaccine strategies for the immunotherapy and prevention of cancer
Berzofsky, J. A., Terabe, M., Oh, S., Belyakov, I. M., Ahlers, J. D., Janik, J. E., & Morris, J. C. (2004) · Journal of Clinical Investigation · doi:10.1172/jci21926 · Cited by 259
Hypoxia-Adenosinergic Immunosuppression: Tumor Protection by T Regulatory Cells and Cancerous Tissue Hypoxia
Sitkovsky, M. V., Kjaergaard, J., Lukashev, D., & Ohta, A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0229 · Cited by 253
Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy?
Jacobs, J. F. M., Nierkens, S., Figdor, C. G., de Vries, I. J. M., & Adema, G. J. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70155-3 · Cited by 254
Treg Enhancing Therapies to Treat Autoimmune Diseases
Eggenhuizen, P. J., Ng, B. H., & Ooi, J. D. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197015 · Cited by 252
Tumor-Associated Macrophages Recruit CCR6+ Regulatory T Cells and Promote the Development of Colorectal Cancer via Enhancing CCL20 Production in Mice
Liu, J., Zhang, N., Li, Q., Zhang, W., Fang, K., Leng, Q., Wang, H., Chen, J., & Wang, H. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019495 · Cited by 263
The ICOS/ICOSL Pathway Is Required for Optimal Antitumor Responses Mediated by Anti–CTLA-4 Therapy
Fu, T., He, Q., & Sharma, P. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1138 · Cited by 243
Depletion of CD4+CD25+ human regulatory T cells in vivo: Kinetics of Treg depletion and alterations in immune functions in vivo and in vitro
Mahnke, K., Schönfeld, K., Fondel, S., Ring, S., Karakhanova, S., Wiedemeyer, K., Bedke, T., Johnson, T., Storn, V., Schallenberg, S., et al. (2007) · International Journal of Cancer · doi:10.1002/ijc.22617 · Cited by 245
Cutaneous T-cell lymphoma: malignant proliferation of T-regulatory cells
Berger, C. L., Tigelaar, R. E., Cohen, J. V., Mariwalla, K., Trinh, J., Wang, N., & Edelson, R. L. (2004) · Blood · doi:10.1182/blood-2004-06-2181 · Cited by 242
Synergistic activation of dendritic cells by combined Toll-like receptor ligation induces superior CTL responses in vivo
Warger, T., Osterloh, P., Rechtsteiner, G., Faßbender, M., Heib, V., Schmid, B., Schmitt, E., Schild, H., & Radsak, M. P. (2006) · Blood · doi:10.1182/blood-2005-10-4015 · Cited by 241
Dynamic versus static biomarkers in cancer immune checkpoint blockade: unravelling complexity
Lesterhuis, W. J., Bosco, A., Millward, M., SMALL, M. P., Nowak, A. K., & Lake, R. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.233 · Cited by 244
OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal
Linch, S. N., McNamara, M. J., & Redmond, W. L. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00034 · Cited by 243
Dendritic Cell Vaccination in Combination with Anti-CD25 Monoclonal Antibody Treatment: A Phase I/II Study in Metastatic Melanoma Patients
Jacobs, J. F. M., Punt, C. J. A., Lesterhuis, W. J., Sutmuller, R. P. M., Brouwer, H., Scharenborg, N. M., Klasen, I. S., Hilbrands, L. B., Figdor, C. G., de Vries, I. J. M., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1757 · Cited by 243
Self-citation
Increasing Tumor Antigen Expression Overcomes “Ignorance” to Solid Tumors via Crosspresentation by Bone Marrow-Derived Stromal Cells
Spiotto, M. T., Yu, P., Rowley, D. A., Nishimura, M. I., Meredith, S. C., Gajewski, T. F., Fu, Y., & Schreiber, H. W. (2002) · Immunity · doi:10.1016/s1074-7613(02)00480-6 · Cited by 234
Regulatory T Cells in Ovarian Cancer: Biology and Therapeutic Potential
Barnett, B. G., Kryczek, I., Cheng, P. J., Zou, W., & Curiel, T. J. (2005) · American Journal of Reproductive Immunology · doi:10.1111/j.1600-0897.2005.00330.x · Cited by 236
Induction of antigen-specific immunologic tolerance by in vivo and in vitro antigen-specific expansion of naturally arising Foxp3+CD25+CD4+ regulatory T cells
Nishimura, E., Sakihama, T., Setoguchi, R., Tanaka, K., & Sakaguchi, S. (2004) · International Immunology · doi:10.1093/intimm/dxh122 · Cited by 232
TGF‐β: a mobile purveyor of immune privilege
Wahl, S. M., Wen, J., & Moutsopoulos, N. M. (2006) · Immunological Reviews · doi:10.1111/j.1600-065x.2006.00437.x · Cited by 229
Cell intrinsic mechanisms of T‐cell inhibition and application to cancer therapy
Peggs, K. S., Quezada, S. A., & Allison, J. P. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00649.x · Cited by 232
Self-citation
Tumor-derived CD4+CD25+ regulatory T cell suppression of dendritic cell function involves TGF-β and IL-10
Larmonier, N., Marron, M., Zeng, Y., Cantrell, J., Romanoski, A., Sepassi, M., Thompson, S., Chen, X., Andreansky, S. S., & Katsanis, E. (2006) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-006-0160-8 · Cited by 229
CD4+ T‐regulatory cells: toward therapy for human diseases
Allan, S., Broady, R. C., Gregori, S., Himmel, M. E., Locke, N. R., Roncarolo, M. G., Bacchetta, R., & Levings, M. K. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00634.x · Cited by 225
CD4+CD25+Foxp3+ T Cells and CD4+CD25−Foxp3+ T Cells in Aged Mice
Nishioka, T., Shimizu, J., Iida, R., Yamazaki, S., & Sakaguchi, S. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.11.6586 · Cited by 220
Glucocorticoid amplifies IL‐2‐dependent expansion of functional FoxP3+CD4+CD25+ T regulatory cells in vivo and enhances their capacity to suppress EAE
Chen, X., Oppenheim, J. J., Winkler-Pickett, R. T., Ortaldo, J. R., & Howard, O. M. Z. (2006) · European Journal of Immunology · doi:10.1002/eji.200635873 · Cited by 221
Depletion of CD25(+) CD4(+) T cells and treatment with tyrosinase-related protein 2-transduced dendritic cells enhance the interferon alpha-induced, CD8(+) T-cell-dependent immune defense of B16 melanoma.
Steitz, J., Brück, J., Lenz, J., Knop, J., & Tüting, T. (2001) · PubMed · Cited by 214
Vitiligo pathogenesis: autoimmune disease, genetic defect, excessive reactive oxygen species, calcium imbalance, or what else?
Paus, R., Schallreuter, K. U., Bahadoran, P., Picardo, M., Slominski, A. T., Elassiuty, Y. E., Kemp, E. H., Giachino, C., Liu, J. B., Luiten, R. M., et al. (2008) · Experimental Dermatology · doi:10.1111/j.1600-0625.2007.00666_1.x · Cited by 216
Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma
Quezada, S. A., Peggs, K. S., Simpson, T. R., Shen, Y., Littman, D. R., & Allison, J. P. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20080099 · Cited by 220
Self-citation
T-lymphocyte homing: an underappreciated yet critical hurdle for successful cancer immunotherapy
Sackstein, R., Schatton, T., & Barthel, S. R. (2017) · Laboratory Investigation · doi:10.1038/labinvest.2017.25 · Cited by 220
Natural Regulatory T Cells and De Novo-Induced Regulatory T Cells Contribute Independently to Tumor-Specific Tolerance
Zhou, G., & Levitsky, H. I. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.4.2155 · Cited by 220
CD4+FoxP3+ regulatory T cells gradually accumulate in gliomas during tumor growth and efficiently suppress antiglioma immune responses in vivo
Grauer, O. M., Nierkens, S., Bennink, E. J., Toonen, L. W. J., Boon, L., Wesseling, P., Sutmuller, R. P. M., & Adema, G. J. (2007) · International Journal of Cancer · doi:10.1002/ijc.22607 · Cited by 217
Self-citation
Cancer drug-tolerant persister cells: from biological questions to clinical opportunities
Russo, M., Chen, M., Mariella, E., Peng, H., Rehman, S. K., Sancho, E., Sogari, A., Toh, T. S., Balaban, N. Q., Batlle, E., et al. (2024) · Nature Reviews Cancer · doi:10.1038/s41568-024-00737-z · Cited by 210
Depletion of CD25+ regulatory cells results in suppression of melanoma growth and induction of autoreactivity in mice.
Jones, E., Dahm‐Vicker, M., Simon, A. K., Green, A., Powrie, F. M., Cerundolo, V., & Gallimore, A. (2002) · PubMed · Cited by 208
Sensitization to immune checkpoint blockade through activation of a STAT1/NK axis in the tumor microenvironment
Zemek, R. M., de Jong, E., Chin, W. L., Schuster, I. S., Fear, V. S., Casey, T. H., Forbes, C., Dart, S., Leslie, C., Zaitouny, A., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav7816 · Cited by 213
Restoring Immune Function of Tumor-Specific CD4+ T Cells during Recurrence of Melanoma
Goding, S. R., Wilson, K. A., Xie, Y., Harris, K. M., Baxi, A. B., Akpınarlı, A., Fulton, A. M., Tamada, K., Strome, S. E., & Antony, P. A. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1300271 · Cited by 208
Regulatory CD4+CD25+ T Cells Restrict Memory CD8+ T Cell Responses
Kursar, M., Bonhagen, K., Fensterle, J., Köhler, A. C., HURWITZ, R. M., Kamradt, T., Kaufmann, S. H. E., & Mittrücker, H. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20011347 · Cited by 204
Toll-like receptors on regulatory T cells: expanding immune regulation
Sutmuller, R. P. M., Morgan, M. E., Netea, M. G., Grauer, O. M., & Adema, G. J. (2006) · Trends in Immunology · doi:10.1016/j.it.2006.06.005 · Cited by 207
Self-citation
DNA Vaccines: Developing New Strategies against Cancer
Fioretti, D. P., Iurescia, S., Fazio, V. M., & Rinaldi, M. (2010) · BioMed Research International · doi:10.1155/2010/174378 · Cited by 204
Negative regulators of T‐cell activation: potential targets for therapeutic intervention in cancer, autoimmune disease, and persistent infections
Pentcheva‐Hoang, T., Corse, E., & Allison, J. P. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00763.x · Cited by 203
Self-citation
Agonist Anti-GITR Antibody Enhances Vaccine-Induced CD8+ T-Cell Responses and Tumor Immunity
Cohen, A. D., Diab, A. K., Perales, M., Wolchok, J. D., Rizzuto, G. A., Merghoub, T., Huggins, D., Liu, C., Turk, M. J., Restifo, N. P., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2813 · Cited by 209
Photodynamic therapy plus low-dose cyclophosphamide generates antitumor immunity in a mouse model
Castano, A. P., Mroz, P., Wu, M. X., & Hamblin, M. R. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709256105 · Cited by 201
CD4+CD25+ T Regulatory Cells, Immunotherapy of Cancer, and Interleukin-2
Antony, P. A., & Restifo, N. P. (2005) · Journal of Immunotherapy · doi:10.1097/01.cji.0000155049.26787.45 · Cited by 202
The architectural pattern of FOXP3-positive T cells in follicular lymphoma is an independent predictor of survival and histologic transformation
Farinha, P., Al-Tourah, A. J., Gill, K. K., Klasa, R. J., Connors, J. M., & Gascoyne, R. D. (2009) · Blood · doi:10.1182/blood-2009-07-235598 · Cited by 208
Extended Dose Ipilimumab with a Peptide Vaccine: Immune Correlates Associated with Clinical Benefit in Patients with Resected High-Risk Stage IIIc/IV Melanoma
Sarnaik, A. A., Yu, B., Yu, D., Morelli, D., Hall, M. S., Bogle, D., Yan, L. E., Targan, S., Solomon, J. C., Nichol, G. M., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2463 · Cited by 200
Suppression, subversion and escape: the role of regulatory T cells in cancer progression
Oļeiņika, K., Nibbs, R. J. B., Graham, G. J., & Fraser, A. R. (2012) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2012.04657.x · Cited by 201
Controlled Local Delivery of CTLA-4 Blocking Antibody Induces CD8+ T-Cell–Dependent Tumor Eradication and Decreases Risk of Toxic Side Effects
Fransen, M. F., van der Sluis, T. C., OSSENDORP, F. A., Arens, R., & Melief, C. J. M. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0781 · Cited by 198
Self-citation
Costimulatory pathways in transplantation: challenges and new developments
Li, X. C., Rothstein, D. M., & Sayegh, M. H. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00781.x · Cited by 199
Tumor-Infiltrating Foxp3−CD4+CD25+ T Cells Predict Poor Survival in Renal Cell Carcinoma
Siddiqui, S. A., Frigola, X., Bonne-Année, S., Mercader, M., Kuntz, S. M., Krambeck, A. E., Sengupta, S., Dong, H., Cheville, J. C., Lohse, C. M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2139 · Cited by 199
A comprehensive review of immune checkpoint inhibitors for cancer treatment
Hossain, M. A. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113365 · Cited by 213
Reduced skin homing by functional Treg in vitiligo
Klarquist, J., Denman, C. J., Hernandez, C., Wainwright, D. A., Strickland, F. M., Overbeck, A., Mehrotra, S., Nishimura, M. I., & Poole, I. C. L. (2010) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2010.00688.x · Cited by 194
CD4+/CD25+ Regulatory Cells Inhibit Activation of Tumor-Primed CD4+ T Cells with IFN-γ-Dependent Antiangiogenic Activity, as well as Long-Lasting Tumor Immunity Elicited by Peptide Vaccination
Casares, N., Arribillaga, L., Sarobe, P., Dotor, J., de Cerio, A. L.-D., Melero, I., Prìeto, J., Borrás‐Cuesta, F., & Lasarte, J. J. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.11.5931 · Cited by 194
Cancer immunosuppression and autoimmune disease: beyond immunosuppressive networks for tumour immunity
Kim, R., Emi, M., & Tanabe, K. (2006) · Immunology · doi:10.1111/j.1365-2567.2006.02430.x · Cited by 195
Conditional Regulatory T-Cell Depletion Releases Adaptive Immunity Preventing Carcinogenesis and Suppressing Established Tumor Growth
Teng, M. W. L., Ngiow, S. F., von Scheidt, B., McLaughlin, N. M., Sparwasser, T. D., & Smyth, M. J. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1681 · Cited by 197
Regulatory T Cells and Human Disease
Cools, N., Ponsaerts, P., Tendeloo, V. F. V., & Berneman, Z. N. (2007) · Clinical and Developmental Immunology · doi:10.1155/2007/89195 · Cited by 194
Epigenetics and immunotherapy: The current state of play
Dunn, J., & Rao, S. (2017) · Molecular Immunology · doi:10.1016/j.molimm.2017.04.012 · Cited by 192
Multivalent RNA aptamers that inhibit CTLA-4 and enhance tumor immunity.
Santulli-Marotto, S., Nair, S. K., Rusconi, C. P., Sullenger, B. A., & Gilboa, E. (2003) · PubMed · Cited by 188
Targeting TNFR2 with antagonistic antibodies inhibits proliferation of ovarian cancer cells and tumor-associated T regs
Torrey, H., Butterworth, J., Mera, T., Okubo, Y., Wang, L., Baum, D., DEFUSCO, A. A., Plager, S., Warden, S., Huang, D., et al. (2017) · Science Signaling · doi:10.1126/scisignal.aaf8608 · Cited by 184
Escape from immunotherapy: possible mechanisms that influence tumor regression/progression
Ahmad, M., Rees, R., & Ali, S. (2004) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-004-0540-x · Cited by 186
Bioactive Compounds: Natural Defense Against Cancer?
Subramaniam, S., Selvaduray, K. R., & Radhakrishnan, A. K. (2019) · Biomolecules · doi:10.3390/biom9120758 · Cited by 183
An evaluation of the clinical significance of FOXP3+ infiltrating cells in human breast cancer
Mahmoud, S., Paish, E. C., Powe, D. G., Macmillan, R. D., Lee, A. H. S., Ellis, I. O., & Green, A. R. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0987-8 · Cited by 191
Immunology beats cancer: a blueprint for successful translation
Pardoll, D. M. (2012) · Nature Immunology · doi:10.1038/ni.2392 · Cited by 182
Combination Therapy with Anti–CTL Antigen-4 and Anti-4-1BB Antibodies Enhances Cancer Immunity and Reduces Autoimmunity
Kocak, E., Lute, K. D., Chang, X., May, K. F., Exten, K. R., Zhang, H., Abdessalam, S. F., Lehman, A. M., Jarjoura, D. G., Zheng, P., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2128 · Cited by 177
Cancer immunotherapy
Baxevanis, C. N., Perez, S. A., & Papamichail, M. (2009) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408360902937809 · Cited by 183
CTLA‐4: a key regulatory point in the control of autoimmune disease
Scalapino, K. J., & Daikh, D. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00639.x · Cited by 177
The role of suppressor T cells in regulation of immune responses
McHugh, R. S., & Shevach, E. M. (2002) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2002.129339 · Cited by 173
Glucocorticoid-Induced TNF Receptor Family Related Gene Activation Overcomes Tolerance/Ignorance to Melanoma Differentiation Antigens and Enhances Antitumor Immunity
Ramirez‐Montagut, T., Chow, A. T., Hirschhorn-Cymerman, D., Terwey, T. H., Kochman, A. A., Lu, S. X., Miles, R. C., Sakaguchi, S., Houghton, A. N., & van den Brink, M. R. M. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.11.6434 · Cited by 173
CD27 Signaling Increases the Frequency of Regulatory T Cells and Promotes Tumor Growth
Claus, C., Riether, C., Schürch, C. M., Matter, M. S., Hilmenyuk, T., & Ochsenbein, A. F. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2791 · Cited by 167

Authors: Sutmuller, R. P. M., van Duivenvoorde, L. M., van Elsas, A., Schumacher, T. N. M., Wildenberg, M. E., Allison, J. P., Toes, R. E. M., Offringa, R., & Melief, C. J. M.
Affiliations: Leiden University Medical Center (NL)
aDepartment of Immunohematology and Blood Transfusion, Tumor Immunology Lab, E3-Q, Leiden University Medical Center, 2300 RC Leiden, Netherlands
The Netherlands Cancer Institute (NL)
University of California, Berkeley (US)
ORCID: Schumacher, Ton N.M.
Wildenberg, Manon E.
Allison, James P.
Offringa, Rienk
Melief, Cornelis J.M.
Venue: The Journal of Experimental Medicine
Publisher: Rockefeller University Press
Published: 2001-09-17
Volume: 194
Issue: 6
Pages: 823-832
ISSN: 0022-1007 (ISSN-L)
1540-9538
DOI: 10.1084/jem.194.6.823
PMC: PMC2195955
OpenAlex: W2148911309
Cited by: 1,008
References: 44
Citations by year: 2026: 3 · 2025: 7 · 2024: 8 · 2023: 12 · 2022: 15 · 2021: 15 · 2020: 18 · 2019: 11 · 2018: 12 · 2017: 25 · 2016: 22 · 2015: 36 · 2014: 26 · 2013: 48 · 2012: 41
FWCI: 13.30
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: cc-by-nc-sa
Locations: The Journal of Experimental Medicine (publishedVersion)
PubMed Central (publishedVersion, cc-by-nc-sa)
PubMed (publishedVersion)
Data Archiving and Networked Services (DANS) (submittedVersion)
Pure Amsterdam UMC (submittedVersion)
Topics: Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords: CTLA-4 blockade, CD25+ regulatory T cells, Treg depletion, antitumor immunity, B16 melanoma, CD8+ T cells, tyrosinase-related protein 2, immune regulation, tumor rejection
MeSH terms: Abatacept, Animals, Antibodies, Monoclonal, Antigens, Differentiation, Antigens, Neoplasm, Female, Immunotherapy, Lymphocyte Depletion, Melanoma, Experimental, Mice, Inbred C57BL, Mice, Nude, T-Lymphocytes, Cytotoxic, Tumor Cells, Cultured, Receptors, Interleukin-2, Biomarkers, CD4-Positive T-Lymphocytes, Antigens, CD, Immunoconjugates, Intramolecular Oxidoreductases, Mice, CTLA-4 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25+ regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks